Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions

Stereotact Funct Neurosurg. 2000;75(2-3):66-75. doi: 10.1159/000048385.

Abstract

Object: To investigate the possibility that subthalamic nucleus (STN) ablation could prevent the toxicity of the selective dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA).

Methods: Sixty rats were divided into 6 groups (n = 10). The control group received a unilateral microinjection of 6-OHDA into the right ventral tegmental area (VTA) and the right median forebrain bundle (MFB). Group 1 received an administration of kainic acid (KA) into the right STN and, 1-week later, an injection of 6-OHDA in the right VTA and MFB. Groups 2-5 received an injection of 6-OHDA in the right VTA and MFB, 1 h, 2 h, 3 days, and 7 days before KA in the right STN respectively. Four weeks later, the changes of tyrosine hydroxylase (TH)-positive (dopaminergic) neurons in the SNc were investigated with immunocytochemical and morphometrical methods.

Results: The number of TH-positive cells in the SNc on the injected side of treated groups (groups 1-5) and control group were 71.46 +/- 6.84, 57.07 +/- 5.54, 51.09 +/- 4.85, 12.68 +/- 2.67, 4.15 +/- 1.60 and 3.40 +/- 1.54/slice, which decreased to 96.7, 72.9, 69.8, 17.2, 5.6 and 4.4% of the non-injected side, respectively. The number of TH-positive neurons in groups 1-4 significantly increased in comparison with the controls (p < 0.05, 0.01). In group 5, there were no remarkable differences in contrast to the number of TH-positive neurons of the controls (p > 0.05). The difference in the number of TH-positive neurons between groups 1-5 was statistically significant (p < 0.01).

Conclusion: The results indicate that STN ablation can provide antiglutamate-based neuroprotection of the dopaminergic nigrostriatal pathway against 6-OHDA toxicity.

Publication types

  • Comparative Study

MeSH terms

  • Afferent Pathways / drug effects*
  • Afferent Pathways / physiopathology
  • Animals
  • Biomarkers / analysis
  • Dopamine / physiology*
  • Excitatory Amino Acid Agonists / administration & dosage
  • Excitatory Amino Acid Agonists / toxicity*
  • Glutamic Acid / physiology
  • Kainic Acid / administration & dosage
  • Kainic Acid / therapeutic use*
  • Male
  • Medial Forebrain Bundle / drug effects
  • Microinjections
  • Nerve Degeneration
  • Nerve Tissue Proteins / analysis
  • Neurons / enzymology
  • Neurons / pathology*
  • Neurotoxins / toxicity*
  • Oxidopamine / toxicity*
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / pathology
  • Parkinsonian Disorders / prevention & control*
  • Rats
  • Rats, Wistar
  • Substantia Nigra / pathology*
  • Subthalamic Nucleus / drug effects*
  • Subthalamic Nucleus / physiopathology
  • Tyrosine 3-Monooxygenase / analysis
  • Ventral Tegmental Area / drug effects

Substances

  • Biomarkers
  • Excitatory Amino Acid Agonists
  • Nerve Tissue Proteins
  • Neurotoxins
  • Glutamic Acid
  • Oxidopamine
  • Tyrosine 3-Monooxygenase
  • Kainic Acid
  • Dopamine